Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$1.29 USD
-0.01 (-0.77%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.29 0.00 (0.00%) 6:28 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACRV 1.29 -0.01(-0.77%)
Will ACRV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACRV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRV
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now
Can Humana Beat Q1 Earnings Estimates on Growing Premiums?
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Universal Health to Report Q1 Earnings: Can it Surprise Wall Street?
HCA Healthcare to Report Q1 Earnings: Key Estimates to Note
Can Centene Beat Q1 Earnings Estimates on Growing Premiums?
Other News for ACRV
Acrivon Therapeutics Holds Annual Stockholders Meeting
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating
JonesResearch Downgrades Acrivon Therapeutics (ACRV) to Hold | ACRV Stock News
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
Acrivon Therapeutics, Inc. (ACRV) was downgraded to a Hold Rating at JonesTrading